What is Better Than Ozempic to Lose Weight? Exploring Alternative Weight Loss Solutions

Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The premise of the question needs correcting before it can be answered: Ozempic is not a weight-loss drug. The Ozempic prescribing information carries three indications, all in type 2 diabetes, and no weight-management indication at all. So "better than Ozempic to lose weight" is really two questions — which products are actually approved for weight reduction, and which of those produced the largest reductions in head-to-head evidence. On the second question, the strongest direct comparison available favors tirzepatide over semaglutide. On the first, the approved field is now wider than most people realize.

Start With What Ozempic Is Approved For

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no BMI eligibility criterion anywhere in the label because weight is not what the label is about.

Weight reduction does occur — in a 40-week trial in the label, mean body weight changed by −5.6 kg at 1 mg and −6.4 kg at 2 mg — but those are secondary observations in diabetes trials with glycemic primary endpoints. Comparing them to obesity-trial results is comparing different questions.

Wegovy: The Semaglutide Product Actually Approved for Weight

Same molecule, different application. The Wegovy prescribing information covers reduction of major adverse cardiovascular event risk in adults with established cardiovascular disease and either obesity or overweight; reduction of excess body weight and long-term maintenance in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis in adults.

Wegovy's labeled ceiling has moved. For weight reduction in adults, the maintenance dosage is 1.7 mg or 2.4 mg once weekly, and the label now states that for patients who tolerate 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg once weekly. A 7.2 mg/0.75 mL single-dose pen, Wegovy HD, is among the listed strengths. If someone's honest complaint is that semaglutide stopped working, the answer may not be a different molecule at all.

Zepbound: A Different Mechanism, Larger Average Reductions

Tirzepatide is a dual GIP and GLP-1 receptor agonist rather than a GLP-1 agonist alone. The Zepbound prescribing information indicates it, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Its maximum dosage is 15 mg once weekly.

The obesity program behind it, SURMOUNT-1, ran 72 weeks in 2,539 adults and reported mean weight changes of −15.0%, −19.5% and −20.9% across the three dosages studied, against −3.1% with placebo. Note that Mounjaro, the other tirzepatide brand, is approved only for glycemic control in type 2 diabetes and holds no weight-management indication — same molecule, different application, and the distinction drives insurance coverage.

The Only Head-to-Head Trial That Directly Answers the Question

SURMOUNT-5 was a phase 3b open-label trial that randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) once weekly for 72 weeks. The published results put the least-squares mean percent change in weight at week 72 at −20.2% with tirzepatide versus −13.7% with semaglutide.

That is the cleanest evidence available, and it is worth reading precisely. It compares two specific dose ranges over 72 weeks in people without diabetes, and it predates the 7.2 mg semaglutide maintenance option. Averages also conceal enormous individual spread; a trial mean is not a forecast for any single person.

The Oral Field Has Changed

Two assumptions circulating online are now wrong. First, oral semaglutide exists in more than one form: Rybelsus tablets have been available for years, and the current FDA label covering Rybelsus and Ozempic tablets includes Ozempic tablets at 1.5, 4 and 9 mg for type 2 diabetes and cardiovascular risk reduction. Second, Wegovy tablets were approved in December 2025 at 1.5, 4, 9 and 25 mg with a 25 mg maintenance dosage; they carry two of the injection's indications — weight reduction in adults and cardiovascular risk reduction — but not the pediatric or MASH indications.

Separately, orforglipron reached approval as Foundayo in April 2026 — a once-daily oral non-peptide GLP-1 receptor agonist indicated with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight plus at least one weight-related comorbid condition, taken with or without food and escalated to a maximum of 17.2 mg once daily. There is still no FDA-approved oral tirzepatide and no oral Zepbound.

"Better" Depends on Which Endpoint You Care About

If the goal is the largest average weight reduction, the head-to-head data point toward tirzepatide. If the goal is cardiovascular risk reduction, semaglutide 2.4 mg has the outcome trial: SELECT enrolled 17,604 patients aged 45 and older with preexisting cardiovascular disease and a BMI of 27 or greater without diabetes, and a primary cardiovascular endpoint event occurred in 6.5% on semaglutide versus 8.0% on placebo (hazard ratio 0.80).

If sleep apnea is the driver, Zepbound is the product with that indication. If liver fibrosis from MASH is the concern, Wegovy injection is the product with that one. If swallowing a tablet is the difference between taking a medication and not taking it, the oral options matter more than a percentage point of average loss. "Better" is not a property of a molecule; it is a property of a match between a person and an endpoint, and it is decided with a prescriber.

What Compounded Medications Are and Are Not

Compounded semaglutide and tirzepatide are not FDA-approved finished products. The FDA states that it does not review compounded versions of these drugs for safety, effectiveness, or quality, and it has warned about compounders using salt forms such as semaglutide sodium and semaglutide acetate, which it treats as different active ingredients from the approved products.

Preparations dispensed by licensed 503A compounding pharmacies against an individual prescription occupy a defined regulatory space, but they are not approved equivalents of Wegovy, Ozempic, Zepbound or Mounjaro, and calling them generics misstates both their status and the evidence behind them. Retatrutide, which appears in a lot of speculative coverage, remains investigational and is not available as a treatment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic approved for weight loss?

No. The Ozempic prescribing information lists three indications, all in type 2 diabetes: adjunct to diet and exercise for glycemic control, reduction of major adverse cardiovascular event risk in patients with established cardiovascular disease, and reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in chronic kidney disease. There is no weight-management indication and no BMI eligibility criterion in the label. Wegovy is the semaglutide product approved for weight reduction.

Does tirzepatide produce more weight loss than semaglutide?

In the one direct head-to-head trial, yes. SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of tirzepatide, 10 mg or 15 mg, or of semaglutide, 1.7 mg or 2.4 mg, once weekly for 72 weeks. The least-squares mean percent weight change at week 72 was minus 20.2% with tirzepatide versus minus 13.7% with semaglutide. Individual results varied widely.

Is there an oral alternative to injections?

Several. Rybelsus and Ozempic tablets are oral semaglutide products labeled for type 2 diabetes and cardiovascular risk reduction. Wegovy tablets were approved in December 2025 at 1.5, 4, 9 and 25 mg for weight reduction and cardiovascular risk reduction in adults. Foundayo, oral orforglipron, is a once-daily non-peptide GLP-1 receptor agonist approved in April 2026 for weight reduction. There is no FDA-approved oral tirzepatide.

What is the highest approved semaglutide dose for weight reduction?

The Wegovy label states that for adults who tolerate the 2.4 mg maintenance dosage for at least four weeks and for whom additional weight reduction is clinically indicated, the dosage may be increased to a maximum of 7.2 mg subcutaneously once weekly. A 7.2 mg per 0.75 mL single-dose pen, Wegovy HD, appears among the listed strengths. Whether that step is appropriate for any individual is a prescriber decision.

Is compounded semaglutide a cheaper version of Ozempic?

It is not an approved equivalent of anything. The FDA states it does not review compounded versions of these drugs for safety, effectiveness, or quality, and has warned that some compounders use salt forms such as semaglutide sodium and semaglutide acetate, which it considers different active ingredients from the approved products. Compounded preparations from licensed 503A pharmacies are made against individual prescriptions and are not approved generics.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.